Pramipexole in Out-patients With Idiopathic Restless Legs Syndrome (IRLS)

Model scores of the 29,894 trials active now.

Model score 9% for any early termination, 2% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 15% of the time (734 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2009-06-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Sponsor's past termination rate: 2.7% (lowers risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Trials the sponsor started in the prior 2 years: 172 (lowers risk) · Sponsor's track record
• Has a data monitoring committee: not given (lowers risk) · Design
• Design: parallel (raises risk) · Design
• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: placebosclerosissymptomsdiseaseto determine
  Phrases that lowered it: at screeningclinical14 dayssevererange
• Phase: 3 (lowers risk) · Design
• Drug's FAERS reports with a death: 8.0% (lowers risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Disease area, psychiatry: Yes (raises risk) · Disease area
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Disease area, cancer: No (lowers risk) · Disease area
• Blinding: quadruple (lowers risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Sponsor's past trials: 73 (lowers risk) · Sponsor's track record
• Disease area, neurology: Yes (raises risk) · Disease area
• Drug's FAERS reports before start: 348 (lowers risk) · Drug's FDA history
• Responsible party: sponsor (lowers risk) · Design
• Keywords listed: 0 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Clinical Trial Assessing the Efficacy and Safety of BP1.4979 in Restless Legs Syndrome NCT03345953 · started 2018 · scored riskier than 58% of active trials terminated
• Efficacy and Safety Study of Aplindore in Patients With Restless Legs Syndrome NCT00834327 · started 2009 · scored riskier than 91% of active trials terminated
• The Effects of Aplindore on the Treatment of Signs and Symptoms of Restless Legs Syndrome NCT00626418 · started 2008 · scored riskier than 12% of active trials completed
• Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS) NCT01569464 · started 2012 · scored riskier than 34% of active trials completed
• Dose Escalating Study of Rotigotine in Pediatric Subjects With Restless Legs Syndrome NCT01495793 · started 2011 · scored riskier than 19% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.